Lenvatinib | B1157

Lenvatinib is a potent inhibitor of multiple receptor tyrosine kinases, with IC₅₀ values of 22 nM, 4 nM, 5.2 nM, 39 nM and 35 nM on VEGFR-1, VEGFR-2, VEGFR-3, PDGFRβ and RET, respectively. It inhibits SCF- and VEGF-induced angiogenesis of human umbilical vein endothelial cells that express the SCF receptor KIT, with IC₅₀ values of 5.2 nM and 5.1 nM, respectively. Lenvatinib inhibits tumor growth in the human small cell lung cancer H146 xenograft model.

Lenvatinib is a potent inhibitor of multiple receptor tyrosine kinases, with IC₅₀ values of 22 nM, 4 nM, 5.2 nM, 39 nM and 35 nM on VEGFR-1, VEGFR-2, VEGFR-3, PDGFRβ and RET, respectively. It inhibits SCF- and VEGF-induced angiogenesis of human umbilical vein endothelial cells that express the SCF receptor KIT, with IC₅₀ values of 5.2 nM and 5.1 nM, respectively. Lenvatinib inhibits tumor growth in the human small cell lung cancer H146 xenograft model.

B1157 | Lenvatinib DataSheet

Alternate Name/Synonyms: 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxyquinoline-6-carboxamide; E7080

Appearance: Crystalline solid

Formulation: N/A

CAS Number: 417716-92-8

Structure Available?: Yes

Peptide sequence: N/A

Salt Form: No

Molecular Formula: C₂₁H₁₉ClN₄O₄

Molecular Weight: 426.85

Cell-Permeable?: Yes

Purity: ≥98% by HPLC

Solubilities: DMSO (>35 mg/ml)

Handling: Protect from air and light

Country of Origin: USA

Tag Line: A potent inhibitor of multiple receptor tyrosine kinases

MDL Number: N/A

PubChem CID: 9823820

SMILES: COC1=CC2=NC=CC(=C2C=C1C(=O)N)OC3=CC(=C(C=C3)NC(=O)NC4CC4)Cl

InChi: InChI=1S/C21H19ClN4O4/c1-29-19-10-17-13(9-14(19)20(23)27)18(6-7-24-17)30-12-4-5-16(15(22)8-12)26-21(28)25-11-2-3-11/h4-11H,2-3H2,1H3,(H2,23,27)(H2,25,26,28)

InChi Key: WOSKHXYHFSIKNG-UHFFFAOYSA-N